3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Interventions
Rituximab
6
venetoclax
5
Bendamustine Hydrochloride
5
obinutuzumab
3
acalabrutinib
3
zanubrutinib
2
pirtobrutinib
2
idelalisib
2
ibrutinib
2
Chlorambucil
2
umbralisib
1
ublituximab
1
ofatumumab
1
fludarabine phosphate
1
duvelisib
1
atezolizumab
1
Pharmacogenomic Testing
1
Cyclophosphamide
1
CT-P10
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
Leukemia, Lymphocytic, Chronic, B-Cell
×
ublituximab
×
Clear all
NCT02793583
2022-07-21
UNITY-NHL
TG Therapeutics, Inc.
Phase 2/3
Terminated
710 enrolled
1 FDA